SOTAC Stock Overview
Manufactures and sells a range of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sotac Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹154.05 |
| 52 Week High | ₹202.80 |
| 52 Week Low | ₹87.10 |
| Beta | 0 |
| 11 Month Change | 35.13% |
| 3 Month Change | 24.18% |
| 1 Year Change | 23.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.58% |
Recent News & Updates
We Think Sotac Pharmaceuticals (NSE:SOTAC) Is Taking Some Risk With Its Debt
Jul 24
Sotac Pharmaceuticals Limited's (NSE:SOTAC) 31% Price Boost Is Out Of Tune With Earnings
Jun 28Recent updates
Shareholder Returns
| SOTAC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -18.5% | 0.2% | -2.0% |
| 1Y | 23.2% | 47.9% | 42.8% |
Return vs Industry: SOTAC underperformed the Indian Pharmaceuticals industry which returned 47.9% over the past year.
Return vs Market: SOTAC underperformed the Indian Market which returned 42.8% over the past year.
Price Volatility
| SOTAC volatility | |
|---|---|
| SOTAC Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SOTAC's share price has been volatile over the past 3 months.
Volatility Over Time: SOTAC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Sharadkumar Patel | sotacpharma.com |
Sotac Pharmaceuticals Limited manufactures and sells a range of pharmaceutical products in India and internationally. The company offers non-beta-lactam tablets; beta-lactam tablets; non-beta-lactam capsules; beta-lactam capsules; oral liquids; dry syrups; and external preparations, such as nasal sprays, relief sprays, and creams. Its therapeutic portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, antiallergic, derma products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, antipyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin.
Sotac Pharmaceuticals Limited Fundamentals Summary
| SOTAC fundamental statistics | |
|---|---|
| Market cap | ₹1.70b |
| Earnings (TTM) | ₹42.81m |
| Revenue (TTM) | ₹1.04b |
39.8x
P/E Ratio1.6x
P/S RatioIs SOTAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOTAC income statement (TTM) | |
|---|---|
| Revenue | ₹1.04b |
| Cost of Revenue | ₹796.12m |
| Gross Profit | ₹242.19m |
| Other Expenses | ₹199.38m |
| Earnings | ₹42.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.87 |
| Gross Margin | 23.33% |
| Net Profit Margin | 4.12% |
| Debt/Equity Ratio | 50.4% |
How did SOTAC perform over the long term?
See historical performance and comparison